Oncovir
Activating Innate & Adaptive Immunity to Fight Cancer
Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders.
We promote Hiltonol® (poly-ICLC) as an experimental viral mimic and broad activator of innate and adaptive immunity. While initially developed as an interferon inducer, Hiltonol® has much broader biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.
LATEST NEWS
12.2.2021
ISR Vaccine AB signs contract with Oncovir Inc for the adjuvant to the vaccine
”The well-used adjuvant from Oncovir fits nicely with our vaccine formulation, which together
with full length spike mimics the natural SARS-CoV-2 infection with induction of antibodies and
a strong T cell response. In our preclinical studies we have been very impressed by the
stimulatory direction of the adjuvant and with the lack of side effects in the doses used in
respiratory tract administration”, comments Ola Winqvist, CEO ISR.